L V McFarland
Overview
Explore the profile of L V McFarland including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
1825
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
McFarland L, Ship N, Auclair J, Millette M
J Hosp Infect
. 2018 Apr;
99(4):443-452.
PMID: 29702133
Clostridium difficile infection (CDI) has become the leading healthcare-associated infection and cause of outbreaks around the world. Although various innovative treatments have been developed, preventive strategies using multi-faceted infection control...
2.
Zorzela L, Ardestani S, McFarland L, Vohra S
Benef Microbes
. 2017 Sep;
8(5):739-754.
PMID: 28884589
Our objective was to conduct a systematic review and meta-analysis for the use of modified (heat-killed or sonicated) probiotics for the efficacy and safety to prevent and treat various diseases....
3.
Goldstein E, Johnson S, Maziade P, Evans C, Sniffen J, Millette M, et al.
Anaerobe
. 2016 Dec;
45:114-119.
PMID: 27988389
The role of probiotics as adjunctive measures in the prevention of Clostridium difficile infection (CDI) has been controversial. However, a growing body of evidence has suggested that they have a...
4.
Littman A, McFarland L, Thompson M, Bouldin E, Arterburn D, Majerczyk B, et al.
Disabil Health J
. 2015 Jan;
8(3):325-35.
PMID: 25612803
Background: Obesity is thought to be highly prevalent in persons with lower extremity amputations (LEAs) and can impair physical and social functioning. Objective: The aim of this study was to...
5.
McFarland L
Benef Microbes
. 2014 Jun;
6(2):189-94.
PMID: 24889895
Meta-analyses are used to evaluate pooled effects of a wide variety of investigational agents, but the interpretation of the results into clinical practices may be difficult. This mini-review offers a...
6.
Elmer G, McFarland L
Gastroenterol Clin North Am
. 2001 Oct;
30(3):837-54.
PMID: 11586560
Biotherapeutic agents offer unique advantages over traditional treatments for infectious diarrhea, and several have been shown to be effective (Table 4). These therapeutic microbial agents are most effective in types...
7.
McFarland L
Eur J Gastroenterol Hepatol
. 2000 Nov;
12(10):1069-71.
PMID: 11057450
Normal microbial flora support the health of the host by diverse mechanisms. When antibiotics, stress, disease or medications disrupt normal microflora, the ability to ward off infection by pathogens is...
8.
Surawicz C, McFarland L, Greenberg R, Rubin M, FEKETY R, Mulligan M, et al.
Clin Infect Dis
. 2000 Oct;
31(4):1012-7.
PMID: 11049785
Recurrent Clostridium difficile disease (CDD) is a difficult clinical problem because antibiotic therapy often does not prevent further recurrences. In a previous study, the biotherapeutic agent Saccharomyces boulardii was used...
9.
McFarland L, Brandmarker S, Guandalini S
J Pediatr Gastroenterol Nutr
. 2000 Sep;
31(3):220-31.
PMID: 10997362
No abstract available.
10.
McFarland L
Curr Gastroenterol Rep
. 2000 Sep;
1(4):301-7.
PMID: 10980964
Bacterial and viral diarrhea remain important causes of morbidity and mortality throughout the world. Current concerns with medical costs, increasing frequency of antibiotic resistance, and overuse of antibiotics in general...